耐多药肺结核患者不同化疗方案疗效及不良反应的临床观察  

Curative effects and adverse reaction of different chemotherapies for patients with multi-drug resistant pulmonary tuberculosis

作　　者：刘会[1] 董雅坤[1] 张娜 陈素丽[1] 刘锐[1] 张晓光[1] 

机构地区：[1]河北省胸科医院结核内科,河北石家庄050041 [2]河北省望都县医院重症医学科,河北望都072450

出　　处：《河北医科大学学报》2015年第3期265-268,共4页Journal of Hebei Medical University

基　　金：河北省科学技术研究与发展指导计划项目(122777111)

摘　　要：目的观察及分析耐多药肺结核患者不同化疗方案临床疗效及不良反应。方法耐多药肺结核患者81例随机分为A组41例和B组40例,A组采用以氟喹诺酮类莫西沙星及注射用药阿米卡星为核心、B组采用以氟喹诺酮类左氧氟沙星及注射用药卷曲霉素为核心治疗方案,比较分析2组临床表现、不同时间的痰菌转阴率、影像学表现及治疗前后的相关不良反应等。结果 A组治疗早期(治疗2个月末)临床有效率、痰菌转阴率及影像学病灶吸收方面优于对照组(P<0.05),而2组不良反应比较差异无统计学意义(P>0.05)。结论对于耐多药肺结核患者应用6 MfxAmPaZE/18 MfxPaZE治疗方案安全、有效,且在早期疗效方面更优。Objective To study the clinical effects and adverse reaction of different chemotherapies for patients with multi-drug resistant pulmonary tuberculosis.Methods Eightyone patients with multi-drug resistant pulmonary tuberculosis were randomly divided into A group（moxifloxacin and amikacin group,41 cases） and B group（levofloxacin and capreomycin group,40 cases）,then the clinical manifestations,sputum negative conversion rate,image performance and adverse reaction before and after treatment were compared between two groups.Results The clinical effect,sputum negative conversion rate and the image performance of A group at early treatment（treatment at two months） were superior to those of group B（P〈0.05）.However,there were no significant differences in adverse reactions between two groups（P〉0.05）.Conclusion The 6 MfxAmpaZE/18 Mfx PaZE prescription in the treatment of multi-drug resistant pulmonary tuberculosis is safe and effective,especially in the early treatment stage.

关 键 词：结核 肺 广泛耐药结核 药物毒性 

分 类 号：R521[医药卫生—内科学]